BioCentury
ARTICLE | Clinical News

AnergiX: Phase I/II

November 6, 2000 8:00 AM UTC

Final results from CRXA's 31-patient Phase I/II trial showed that AnergiX.RA was safe and well tolerated at intravenous doses ranging from 0.5-150 ug/kg when given together with methotrexate, with no ...